Healthcare Professional Webinars: PERT and what to do during current shortages (Please note: that these webinars are specifically for healthcare professionals: including hospital clinicians/prescribers, GPs, CNSs & both hospital and community pharmacists) Many of...
Neuroendocrine Cancer UK Announces Partnership with RareCan to help Facilitate Access to Clinical Trial Opportunities Neuroendocrine Cancer UK is excited to announce a partnership with RareCan to help grow cohorts of people with neuroendocrine cancer, empowering them...
Neuroendocrine cancers (NC) are England’s tenth most prevalent cancer. Yet awareness of these cancers is very low, even among healthcare professionals (HCPs). People living with NC experience inequities in diagnosis, disease management and care due to a lack of...
Ovarian Neuroendocrine Cancer – The Facts The incidence of temporary amenorrhoea or early menopause due to cancer or its treatments varies according to the age, pubertal status, existing ovarian reserve and type of cancer and/or treatment. The risk of menopause...
In UK the incidence of Ovarian Neuroendocrine Cancers is less than 10 women a year: England – Nearly 7,000 women are diagnosed with ovarian cancer every year – 0.1% Neuroendocrine = 7 a year – 33 percent of women with ovarian cancer were diagnosed...
